Androgen deprivation therapy in men with prostate cancer is not associated with COVID-2019 infection

Sabina Davidsson1, Anna Messing Eriksson1, Ruzan Udumyan2

  • 1Department of Urology, Faculty of Medicine and Health, Örebro University Hospital, Örebro University, Örebro, Sweden.

The Prostate
|January 20, 2023
PubMed
Abstract

Insights

Androgen deprivation therapy (ADT) in prostate cancer patients did not reduce SARS-CoV-2 infection risk. Prostate cancer patients were not at higher risk for COVID-19 compared to benign prostatic hyperplasia patients.

Area of Science:

  • Oncology
  • Infectious Diseases
  • Virology

Background:

  • Androgens may influence SARS-CoV-2 infection due to the virus's dependence on androgen-regulated TMPRSS2 for cell entry.
  • Prior studies suggested androgen deprivation therapy (ADT) might lower SARS-CoV-2 infection risk in prostate cancer patients, but findings were inconsistent.

Purpose of the Study:

  • To investigate the association between ADT and the risk of SARS-CoV-2 infection and COVID-19 severity in prostate cancer patients.
  • To compare SARS-CoV-2 infection risk between prostate cancer patients and those with benign prostatic hyperplasia (BPH).

Main Methods:

  • A cohort study included 655 prostate cancer patients and 240 BPH patients in Sweden.
  • Participants completed questionnaires on COVID-19 symptoms and provided blood samples for SARS-CoV-2 IgG antibody testing.
  • Multivariable logistic regression models were used to analyze the association between ADT and SARS-CoV-2 infection risk.

Main Results:

  • The cumulative incidence of SARS-CoV-2 seropositivity was 13.4% for ADT users and 10.4% for non-users.
  • Adjusted analysis revealed no significant difference in SARS-CoV-2 infection risk or symptoms between ADT users and non-users (OR: 0.98; 95% CI: 0.52-1.85).
  • Higher BMI, Type 1 diabetes, and prostate cancer severity (Gleason score 8-10 or PSA >20 µg/l) were associated with increased SARS-CoV-2 infection risk.

Conclusions:

  • The study findings do not support the hypothesis that ADT reduces SARS-CoV-2 infection risk or severity in prostate cancer patients.
  • Prostate cancer patients did not exhibit a higher risk of COVID-19 compared to men with BPH.

Related Concept Videos

Disorders of the Male Reproductive System01:20

Disorders of the Male Reproductive System

Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
510
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
Infertility in Males01:23

Infertility in Males

Male infertility affects millions of couples worldwide, arising from various factors that impact different stages of the reproductive process. An endocrine imbalance resulting from conditions like hypogonadism, Klinefelter syndrome, or pituitary disorders can disrupt hormone levels and reduce sperm production. Testicular defects, such as tumors, cryptorchidism, atrophic testes, abnormal sperm morphology, and low sperm count or motility, may arise due to genetic factors, structural...
312
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.9K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Psychoneuroimmunology: Diabetes and Cancer01:19

Psychoneuroimmunology: Diabetes and Cancer

Chronic stress has been linked to both the onset and progression of serious health conditions, including Type 2 diabetes and cancer. Type 2 diabetes, a widespread chronic illness, is closely associated with obesity and insulin resistance, both of which often worsen under stress. Studies indicate that men experiencing high levels of chronic stress face a 45% higher risk of developing diabetes compared to those with minimal stress. Stress triggers physiological responses that elevate blood...
55